UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the
Registrant ¨ Filed by
a Party other than the Registrant x
Check the appropriate box:
|
|
|
¨ |
|
Preliminary Proxy Statement |
|
|
¨ |
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
¨ |
|
Definitive Proxy Statement |
|
|
x |
|
Definitive Additional Materials |
|
|
¨ |
|
Soliciting Material Pursuant to §240.14a-12 |
AFFYMETRIX, INC.
(Name
of Registrant as Specified in Its Charter)
THERMO FISHER SCIENTIFIC INC.
(Name of Person(s) Filing Proxy Statement, if other than Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
x |
|
No fee required. |
|
|
¨ |
|
Fee computed below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
|
|
|
|
(1) |
|
Title of each class of securities to which transaction applies:
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies:
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction:
|
|
|
(5) |
|
Total fee paid:
|
|
|
¨ |
|
Fee paid previously with preliminary materials. |
|
|
¨ |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing. |
|
|
|
|
|
(1) |
|
Amount Previously Paid:
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.:
|
|
|
(3) |
|
Filing Party:
|
|
|
(4) |
|
Date Filed:
|
News
|
|
|
|
|
FOR IMMEDIATE RELEASE |
|
|
Media Contact Information: Karen
Kirkwood |
|
Investor Contact Information: Ken
Apicerno |
|
|
781-622-1306 |
|
781-622-1294 |
|
|
karen.kirkwood@thermofisher.com |
|
ken.apicerno@thermofisher.com |
|
|
www.thermofisher.com |
|
|
|
|
or Joele Frank, Wilkinson Brimmer Katcher
Joele Frank / Andrea Rose / Averell Withers 212-355-4449 |
|
|
|
|
Thermo Fisher Scientific Issues Open Letter to Affymetrix Stockholders
Agrees with Affymetrix that Acquisition Proposal from Origin Technologies Does Not Constitute, and Could Not Reasonably be Expected to Lead
to, a Superior Proposal
Reiterates Commitment to Completing Affymetrix Transaction as Quickly as Possible, which is in the Best
Interests of All Affymetrix Stockholders
Waltham, Mass. March 20, 2016 Thermo Fisher Scientific (NYSE: TMO), the world leader in
serving science, today commented on the press release of Affymetrix, Inc. that responded to the unsolicited, non-binding proposal received on March 18, 2016, from Origin Technologies Corporation, LLC (the Origin Proposal). Thermo Fisher
agrees with Affymetrix and its board of directors that the Origin Proposal does not constitute, and could not reasonably be expected to lead to, a Superior Proposal as defined in the Agreement and Plan of Merger between Thermo Fisher and
Affymetrix (the Merger Agreement) and that Affymetrix and its board of directors could not reasonably determine otherwise. Thermo Fisher continues to believe that the Merger Agreement remains in the best interests of both Affymetrix and
its stockholders.
The proposal put forth to Affymetrix by Origin Technologies, a newly created shell entity relying on a vague and insufficient
financing package from a Chinese firm, is highly uncertain and speculative and does not constitute, and could not reasonably be expected to lead to, a superior proposal under the Merger Agreement, and Affymetrix and its board of directors could not
reasonably determine otherwise, said Marc N. Casper, president and chief executive officer of Thermo Fisher. Among other reasons, the Origin Proposal was unaccompanied by any proposed merger agreement, is subject to numerous
contingencies, including the completion of due diligence and receipt of external financing from Chinese investors and banks, and has the strong potential for a prolonged and likely unsuccessful regulatory review, particularly as it
relates to CFIUS.
Mr. Casper added, In stark contrast, our merger agreement with Affymetrix, which has been unanimously approved by both
boards of directors, has fully committed financing and has received all necessary regulatory approvals. We are in a position to complete the acquisition immediately following the receipt of Affymetrix stockholder approval this week. We want to
reiterate our continued support and enthusiasm for the imminent completion of our pending transaction, and to emphasize that our agreement continues to represent the most compelling opportunity available for Affymetrix and its stockholders, and
indeed, the only bona fide proposal available. To that end, we stand ready to complete the acquisition, and look forward to welcoming the Affymetrix team to Thermo Fisher.
In connection with this determination, Mr. Casper, on behalf of the Thermo Fisher management team and board
of directors, issued the below letter to Affymetrix stockholders:
March 20, 2016
Dear Affymetrix Stockholders:
I am writing to you today on
behalf of the Thermo Fisher Scientific management team and board of directors regarding the highly uncertain, vague and speculative non-binding proposal that Affymetrix received on March, 18, 2016, from Origin Technologies Corporation, LLC, a newly
created and otherwise unheard of shell entity (the Origin Proposal). Thermo Fisher agrees with Affymetrix and its board of directors that the Origin Proposal does not constitute, and could not reasonably be expected to lead
to, a Superior Proposal as defined in the Agreement and Plan of Merger between Thermo Fisher and Affymetrix, which we entered into on January 8, 2016, and that Affymetrix and its board of directors could not reasonably determine otherwise. With the
scheduled Affymetrix stockholder meeting just days away, we felt it was critical to communicate this immediately.
The Origin Proposal has a number of
fatal inadequacies and shortcomings, including the following:
|
|
|
Despite its claims, the non-binding Origin Proposal is highly contingent, uncertain and insufficient to be considered a bona fide proposal. As you may be aware, the proposal was unaccompanied by any proposed
merger agreement or other transaction documentation and there was no financing commitment documentation beyond a two-page letter from a Chinese private equity fund with limited mergers and acquisitions experience. The total financing contemplated by
that letter, moreover, was woefully short of the amount needed to acquire Affymetrix at the proposed purchase price and fund all related amounts payable under our Merger Agreement with Affymetrix. |
|
|
|
In fact, there is little to no credibility in the marketplace around either the proposed buyer or its financing sources. If Origin Technologies financing terms become too onerous or fluctuate, a significant
possibility in todays market, it could simply walk away from its offer. This means that Affymetrix, a company youve invested your money in, would have extremely limited recourse or ability to pursue Origin Technologies (a shell entity)
or its Chinese financing sources in the United States. |
|
|
|
In addition, there is significant potential for a lengthy and ultimately unsuccessful regulatory review should Affymetrix enter into an agreement with Origin Technologies, an entity purportedly backed by vague
Chinese financing sources. In particular, your advanced technology and longstanding U.S. government work, contracts and grants will draw heightened scrutiny from the Committee on Foreign Investments in the United States (CFIUS). CFIUS has shown a
particular heightened interest in recent years in Chinese investments, and, as we suspect you may be aware, even if CFIUS approval is received, the review process can take many months to complete. |
|
|
|
Furthermore, the timing of the proposal itself which came late on Friday just days before your stockholder meeting and one week before planned close, further undermines the credibility and legitimacy of Origin
Technologies and its proposal, and reinforces the conclusion that it cannot be considered bona fide. As you know, the Merger Agreement between our two companies was publicly announced two-and-a-half months ago. The fact that Origin Technologies
is making a proposal now, unaccompanied by even a draft definitive agreement, when it had access to all the necessary information to formulate and obtain binding financing commitments for a bid months ago, raises serious concern as to whether Origin
Technologies could possibly be expected to execute a definitive agreement and consummate a transaction on a timely basis. |
|
|
|
Further, Origin Technologies has blatantly flouted and violated the U.S. securities laws by failing to make required proxy solicitation filings
with the Securities and Exchange |
|
Commission. If Origin Technologies cannot even manage to comply with the most fundamental federal securities laws, it is hard to imagine how they could ever complete a transaction as
complex as an acquisition of Affymetrix. |
|
|
|
Even if a transaction between Affymetrix and Origin Technologies could be completed, despite these significant risks and contingencies, timing to close would be much more prolonged than the transaction with Thermo
Fisher. Our respective management teams and advisors have been working arm-in-arm and stand ready to close immediately following the receipt of Affymetrix stockholder approval on March 24, 2016. Whats more, we believe that the time to sign
and close under the Origin Proposal would be significantly longer than what was suggested, and that it is highly unlikely that Chinese financing sources can execute binding commitments and move funds to USD and offshore in a timely manner and also
satisfy due diligence needs quickly. |
|
|
|
Finally, this non-binding proposal is subject to a due diligence condition, which means Origin Technologies could walk away from a potential transaction for any or no reason following completion of an indeterminate
due diligence review. |
In stark contrast, our Merger Agreement, which has been unanimously approved by both boards of directors,
contains no financing conditions or contingency. Our agreement represents a fully financed, all-cash offer from our company, an institution with a stellar track record of completing significant and complex mergers and acquisitions. We have received
all required regulatory approvals, and expect to complete the transaction immediately following receipt of Affymetrix stockholder approval this week.
It
bears emphasizing that in addition to the lack of a credible financing strategy and the potential insurmountable regulatory hurdles to the Origin Proposal, the timing of the proposal itself coming at the eleventh hour on the Friday before
your stockholder meeting and one week before our imminent closing, and a full month after the record date for the stockholder meeting further undermines the credibility and legitimacy of Origin Technologies and its proposal.
For all the reasons set forth above, we urge you to conclude, as we and the Affymetrix board of directors have, that the Merger Agreement continues to
represent the most compelling opportunity available to you, as an Affymetrix stockholder, and, indeed, the only bona fide proposal available.
Now,
more than ever, I want to reaffirm our commitment to Affymetrix and emphasize our continued support and enthusiasm for the completion of our pending transaction. We look forward to continuing to work with your management team towards the timely
completion of a successful transaction one that we are confident will create significant value for Affymetrix customers, employees and stockholders.
Sincerely,
Marc N. Casper
JP Morgan is acting as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel.
About Thermo Fisher Scientific
Thermo Fisher Scientific
Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers
accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and
Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This communication contains
forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the
need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers capital spending policies and
government funding policies; the effect of exchange rate fluctuations on international operations; the effect of healthcare reform legislation; use and protection of intellectual property; the effect of changes in governmental regulations; and the
effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to the proposed Affymetrix transaction may not materialize as expected; the Affymetrix transaction not being
timely completed, if completed at all; prior to the completion of the transaction, Affymetrix business experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with
employees, customers, licensees, other business partners or governmental entities, difficulty retaining key employees, and the parties being unable to successfully implement integration strategies or to achieve expected synergies and operating
efficiencies within the expected time-frames or at all. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fishers Annual Report on
Form 10-K for the year ended December 31, 2015 which is on file with the Securities and Exchange Commission (the SEC) and available in the Investors section of Thermo Fishers website under the heading
SEC Filings and in other documents Thermo Fisher files with the SEC, and in Affymetrix Annual Report on Form 10-K for the year ended December 31, 2015 which is on file with the SEC and available in the
Investors section of Affymetrix website, www.Affymetrix.com, under the heading SEC Filings and in other documents Affymetrix files with the SEC. While Thermo Fisher or Affymetrix may elect to
update forward-looking statements at some point in the future, Thermo Fisher and Affymetrix specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as
representing either Thermo Fishers or Affymetrix views as of any date subsequent to today.
Important Additional Information
In connection with the proposed merger, Affymetrix has filed a proxy statement with the SEC. STOCKHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT (INCLUDING
ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC ON FEBRUARY 24, 2016 BECAUSE IT CONTAINS IMPORTANT INFORMATION. Stockholders may obtain a free copy of the proxy statement and any other relevant documents filed with the SEC from the
SECs website at http://www.sec.gov. In addition, stockholders may obtain, without charge, a copy of the proxy statement and other relevant documents at Affymetrix website at investor.Affymetrix.com or by contacting Affymetrix
investor relations department via e-mail at investor@affymetrix.com.
Affymetrix and its directors, executive officers and other members of
its management and employees as well as Thermo Fisher and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Affymetrix stockholders with respect to the merger. Information about
Affymetrix directors and executive officers and their ownership of Affymetrix common stock is set forth in the proxy statement for Affymetrix 2016 Special Meeting of Stockholders related to the merger, Affymetrix Annual
Report on Form 10-K for the fiscal year ended December 31, 2015 and proxy statement for Affymetrix 2015 Annual Meeting of Stockholders. Information about Thermo Fishers directors and executive officers is set forth in the proxy
statement for Thermo Fishers 2015 Annual Meeting of Stockholders. Stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the merger,
including the interests of Affymetrix directors and executive officers in the merger, which may be different than those of Affymetrix stockholders generally, by reading the proxy statement and other relevant documents regarding the
merger, which have been filed with the SEC.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024